Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Regulation of regulatory T cells and tumor‐associated macrophages in gastric cancer tumor microenvironment

View through CrossRef
AbstractIntroductionDespite advancements in the methods for prevention and early diagnosis of gastric cancer (GC), GC continues to be the fifth in incidence among major cancers and the third most common cause of cancer‐related death. The therapeutic effects of surgery and drug treatment are still unsatisfied and show notable differences according to the tumor microenvironment (TME) of GC.MethodsThrough screening Pubmed, Embase, and Web of Science, we identified and summarized the content of recent studies that focus on the investigation of Helicobacter pylori (Hp) infection, regulatory T cells (Tregs), and tumor‐associated macrophages (TAMs) in the TME of GC. Furthermore, we searched and outlined the clinical research progress of various targeted drugs in GC treatment including CTLA‐4, PD‐1\PD‐L1, and VEGF/VEGFR.ResultsIn this review, the findings indicate that Hp infection causes local inflammation and leads to immunosuppressive environment. High Tregs infiltration in the TME of GC is associated with increased induction and recruitment; the exact function of infiltrated Tregs in GC was also affected by phenotypes and immunosuppressive molecules. TAMs promote the development and metastasis of tumors, the induction, recruitment, and function of TAMs in the TME of gastric cancer are also regulated by various factors.ConclusionDiscussing the distinct tumor immune microenvironment (TIME) of GC can deepen our understanding on the mechanism of cancer immune evasion, invasion, and metastasis, help us to reduce the incidence of GC, and guide the innovation of new therapeutic targets for GC eventually.
Title: Regulation of regulatory T cells and tumor‐associated macrophages in gastric cancer tumor microenvironment
Description:
AbstractIntroductionDespite advancements in the methods for prevention and early diagnosis of gastric cancer (GC), GC continues to be the fifth in incidence among major cancers and the third most common cause of cancer‐related death.
The therapeutic effects of surgery and drug treatment are still unsatisfied and show notable differences according to the tumor microenvironment (TME) of GC.
MethodsThrough screening Pubmed, Embase, and Web of Science, we identified and summarized the content of recent studies that focus on the investigation of Helicobacter pylori (Hp) infection, regulatory T cells (Tregs), and tumor‐associated macrophages (TAMs) in the TME of GC.
Furthermore, we searched and outlined the clinical research progress of various targeted drugs in GC treatment including CTLA‐4, PD‐1\PD‐L1, and VEGF/VEGFR.
ResultsIn this review, the findings indicate that Hp infection causes local inflammation and leads to immunosuppressive environment.
High Tregs infiltration in the TME of GC is associated with increased induction and recruitment; the exact function of infiltrated Tregs in GC was also affected by phenotypes and immunosuppressive molecules.
TAMs promote the development and metastasis of tumors, the induction, recruitment, and function of TAMs in the TME of gastric cancer are also regulated by various factors.
ConclusionDiscussing the distinct tumor immune microenvironment (TIME) of GC can deepen our understanding on the mechanism of cancer immune evasion, invasion, and metastasis, help us to reduce the incidence of GC, and guide the innovation of new therapeutic targets for GC eventually.

Related Results

Abstract 2172: Dying tumor cells (tumor debris) stimulate the growth of 4T1 breast cancer tumor in female athymic nude mice
Abstract 2172: Dying tumor cells (tumor debris) stimulate the growth of 4T1 breast cancer tumor in female athymic nude mice
Abstract Current cancer therapies are based on chemotherapy and radiation. These therapeutic approaches can initially reduce the tumor mass or tumor burden by killin...
Abstract POSTER-BIOL-1344: Epigenetic regulation of SPARC in ovarian cancer
Abstract POSTER-BIOL-1344: Epigenetic regulation of SPARC in ovarian cancer
Abstract Background: We have previously reported the tumor suppressor effect of Secreted protein acidic and rich in cysteine (SPARC) in ovarian cancer in vitro and i...
Abstract POSTER-BIOL-1314: Investigating fatty acid beta-oxidation in ovarian cancer cells
Abstract POSTER-BIOL-1314: Investigating fatty acid beta-oxidation in ovarian cancer cells
Abstract Purpose: To investigate the contribution of fatty acid beta-oxidation to the total energy budget of ovarian cancer cells. Experimental proced...
Abstract POSTER-TECH-1106: Rational design of molecularly targeted therapy for GAB2-driven ovarian cancers
Abstract POSTER-TECH-1106: Rational design of molecularly targeted therapy for GAB2-driven ovarian cancers
Abstract Studies of cancer genomes indicate that high-grade serous ovarian cancers, the most aggressive subtype accounting for over 70% of all ovarian cancer deaths,...
Abstract POSTER-BIOL-1352: Notch3 promotes anoikis resistance in ovarian cancer
Abstract POSTER-BIOL-1352: Notch3 promotes anoikis resistance in ovarian cancer
Abstract Epithelial ovarian cancer (EOC) is the most lethal gynecologic cancer. Recently, a number of genome-wide studies in ovarian cancer patient samples have post...
Abstract POSTER-THER-1407: Cytotoxic natural human MAb against ovarian carcinoma
Abstract POSTER-THER-1407: Cytotoxic natural human MAb against ovarian carcinoma
Abstract MAb216 is a human IgM mAb encoded in germline configuration by the immunoglobulin heavy chain VH4-34 gene. This antibody and many others derived from the VH...
Bioelectric Dysregulation in Cancer Initiation, Promotion, and Progression
Bioelectric Dysregulation in Cancer Initiation, Promotion, and Progression
Cancer is primarily a disease of dysregulation – both at the genetic level and at the tissue organization level. One way that tissue organization is dysregulated is by changes in t...
Cancer immunotherapy: potential involvement of mediators
Cancer immunotherapy: potential involvement of mediators
The description of a cell‐free soluble anti‐tumour factor by Carswell et al. in 1975 (Proc Natl Acad Sci USA, 72: 3666–3670) was followed by a long series of experimental and clini...

Back to Top